FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations
International Journal of Molecular Sciences · 27.07.2026 · 27 (15) · 6677
DOI: 10.3390/ijms27156677 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2026. Verfasst von Mena Abdelsayed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Institute for Medical Research, Philadelphia, PA 19096, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Drug Repositioning, Mutation. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The restoration of mutant p53 stability is a highly sought-after strategy in targeted cancer therapy. This study presents a structure-based virtual screening and molecular dynamics approach to nominate FDA-approved drugs as candidate stabilizers of mutant p53 for downstream experimental validation. A virtual screening library of FDA-approved compounds was docked against three representative p53 mutants (7DHY, 7DHZ, and 7V97) to evaluate their binding potential. The prioritized candidates demonstrated consistent, multi-conformer binding affinities. Protein–ligand interaction profiling revealed that the candidate DB09280 possesses a highly dense interaction network, particularly against the V272M and R249S variants. Residue-level analysis of the G245S structural mutant showed that DB09280 uniquely engages His19, a crucial residue for zinc coordination, and forms stabilizing contacts with adjacent flexible loop residues, including ASN35 and PRO32. Subsequent 500 ns molecular dynamics simulations were consistent with DB09280 acting as a putative conformational clamp on the timescale sampled. The ligand-bound (holo) system exhibited substantially reduced global structural drift (RMSD) and attenuated local residue fluctuation (RMSF) within the core domain compared to the highly unstable apo state. Principal component analysis further indicated that DB09280 restricts the broad conformational sampling of the mutant into a stable, dominant basin within the sampled trajectory. Together, these computational findings nominate DB09280 as a promising candidate structural stabilizer of mutant p53 worthy of experimental follow-up. We emphasize that the in silico stabilization observed here is not equivalent to functional rescue of p53 transcriptional activity; biochemical, biophysical, and cell-based assays will be required to establish whether DB09280 restores wild-type-like DNA binding or tumor-suppressor function in mutant p53 contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lankenau Institute for Medical Research, Philadelphia, PA 19096, USA.
- Laboratory of Innovative Technologies, National School of Applied Sciences of Tangier, Abdelmalek Essaadi University, Tetouan 93000, Morocco.
ORCID-Profile: Yassir Boulaamane
Zitieren
APA
Abdelsayed, M., & Boulaamane, Y. (2026). FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations. International Journal of Molecular Sciences, 27(15), 6677. https://doi.org/10.3390/ijms27156677
Vancouver
Abdelsayed M, Boulaamane Y. FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations. International Journal of Molecular Sciences. 2026;27(15):6677. doi:10.3390/ijms27156677
BibTeX
@article{Abdelsayed2026,
author = {Abdelsayed, Mena and Boulaamane, Yassir},
title = {FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6677},
doi = {10.3390/ijms27156677}
}
EUVIMED